Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress

Biotech Investing

Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today reported financial results for the fourth quarter and full year ended December 31, 2017 and provided an overview of the company’s recent business progress. As quoted in the press release: “2017 was a year …

Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today reported financial results for the fourth quarter and full year ended December 31, 2017 and provided an overview of the company’s recent business progress.

As quoted in the press release:

“2017 was a year of consistent and dynamic execution at Ovid Therapeutics,” said Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer of Ovid Therapeutics. “We delivered on a major corporate alliance with Takeda, secured multiple new patents, received additional regulatory designations for several of our programs, and meaningfully advanced our clinical programs. In 2018, we expect to continue this positive momentum. We anticipate topline results later this year from both the OV101 Phase 2 STARS trial in Angelman syndrome and Phase 1b/2a clinical trial of TAK-935/OV935 in developmental and epileptic encephalopathies. As we look ahead, we intend to expand the clinical development of both OV101 and TAK-935/OV935 into additional indications and age groups.”

Click here to read the full press release.

The Conversation (0)
×